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a patient on LTP with recurrent bleedings. Methods: A cost-consequences analysis 
was adopted to assess the economic impact from the NHS and Society perspectives. 
The cost analysis was based on one patient case (type 1 VWD, recurrent gum bleed-
ings), treated with FVIII/VWF and then with VWF concentrate almost devoid of FVIII. 
The costs included direct costs (drug acquisition, hospital admissions, outpatient 
visits, red blood cells units) and indirect costs (working days lost). Data were gathered 
from a questionnaire (Hemophilia Reference Center of Catania). The health care costs 
were calculated by DRG analysis that assessed DRG refund value for day hospital 
and standard hospitalization. The indirect costs were calculated on the basis of the 
annual income average. Results: The analysis showed a reduction of the number 
of bleedings when treating with VWF concentrate almost devoid of FVIII (30 vs 0), 
minimizing the cost per bleeding episodes (€ 87,957 vs € 0), hospitalizations (€ 3,252 vs 
0), monitoring visits (€ 331 vs € 165) and the number of working days lost (26 vs 2). The 
annual health care costs and indirect costs avoided were € 49,684 and € 3,734 respec-
tively. ConClusions: The replacement therapy with VWF concentrate almost devoid 
of FVIII decreased the consumption of hospital resources and reduced the number 
of working days lost per bleedings together with the discomfort related to bleedings.
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objeCtives: TPO-RAs, represent an evidence-based treatment option in the pub-
lic setting for adult patients with chronic ITP in Mexico. TPO-RAs have not been 
directly compared in head-to-head randomized controlled trials (RCTs); however 
an indirect comparison was undertaken using Bayesian metaregression: the overall 
platelet response was significantly higher in patients receiving Romiplostim than 
in those receiving Eltrombopag, estimating an Odds ratio (OR) of eltrombopag vs 
romiplostim as 0.15 (95% CI: 0.02, 0.84). The objective of this study is to compare 
the cost per response of TPO-RAs in chronic adult ITP in Mexico. Methods: A cost 
per response analysis was developed. Dose was derived from RCTs and Summary 
of Product Characteristics. Median dose for romiplostim was 2.5 mcg/kg/week and 
average dose for eltrombopag was 55 mg/day (21.5% of patients received 25mg; 
41% 75mg; and remaining 37.5% 50mg). Costs for romiplostim were based on vials 
used, considering a representative Mexican patient (65kg); for eltrombopag, it was 
based on milligrams needed. Cost assessment included cost of medication, cost of 
administration and in case of eltrombopag, cost of liver monitoring, expressed in 
Mexican pesos. Crude Overall Response Rate (ORR) for romiplostim was 83%. Placebo 
adjusted ORR for eltrombopag was 42% calculated by applying the OR estimated 
from the Bayesian indirect comparison performed by the NICE Evidence Review 
Group. Results: Romiplostim generates a cost per overall platelet response of 
$219,690.80, while eltrombopag yields $374,137.72. ConClusions: Within the TPO-
RAs, romiplostim generates a lower cost per response than eltrombopag, in adult 
patients with chronic ITP in Mexico.
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objeCtives: Belimumab is a novel biological treatment specifically developed for 
the treatment of active, autoantibody positive SLE patients. The purpose of this study 
is to estimate the cost-effectiveness of belimumab for SLE patients from the Spanish 
societal perspective. Methods: A UK cost-effectiveness microsimulation model 
was adapted to the Spanish setting. The analysis compared standard of care (SoC) 
vs. belimumab plus SoC with 2 years maximum treatment duration and a life-time 
horizon. Disease activity reduction seen with belimumab in the BLISS-52 and BLISS-
76 trials, was extrapolated using data from the US Johns Hopkins Lupus Cohort to 
predict impact on long-term organ damage and mortality.. Utility values and unit 
direct costs (treatment, administration, patient´s follow-up and organ damage costs) 
were obtained from UK and Spain published data, respectively. Indirect costs were 
calculated using the Human Capital Approach method. A discount rate of 3% was 
applied to costs and outcomes. Results were expressed as € 2014. Deterministic and 
probabilistic sensitivity analyses (PSA) were conducted to determine the robust-
ness of the results. An additional analysis was conducted to compare societal and 
Spanish National Health System (NHS) perspectives. Results: The cost per life year 
gained (ICER) and cost per QALY (ICUR) for Belimumab were € 16,647 and € 23,158 
respectively. In 68% of scenarios plotted in the PSA, belimumab was a cost-effective 
alternative considering a € 30,000/QALY threshold. From NHS perspective (indirect 
costs excluded), ICER and ICUR were € 25.619 and € 35.640. ConClusions: Base-case 
results show that belimumab is cost-effective from the Spanish societal perspective. 
From the NHS perspective, the model provides results that fall within an acceptable 
threshold considering the prevalence and the severity of the disease. These results 
highlight the importance of adopting a societal perspective, especially in pathologies 
such as SLE which affect young people of working age.
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objeCtives: Evaluate the efficiency of rituximab in maintenance treatment of 
patients with follicular lymphoma (FL) who respond to first line induction with 
rituximab versus observation in Portugal. Methods: Cost-effectiveness (Life 
(vs. all OCs) had lower activity impairment and fewer provider visits, lower indirect 
costs (normal weight: € 7,974; overweight: € 7,825; OC I: € 8,465; OC II: € 9,394; OC III: 
€ 10,437), and lower total direct costs (normal weight: € 516; overweight: € 553; OC I: 
€ 583; OC II: € 605; OC III: € 717), all p< 0.05. ConClusions: Increased BMI is associ-
ated with higher direct and indirect costs and worse health utilities. The findings 
highlight the impact of obesity on health outcomes.
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objeCtives: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
common genetic kidney disease. Currently there is little published information on 
medical resource utilisation (MRU) in European ADPKD patients. This study aimed 
to estimate the health care resource use of ADPKD patients across six European 
countries. Methods: A retrospective review of medical charts was conducted via 
an online physician survey in France, Germany, Italy, Spain, Sweden and the United 
Kingdom (UK). A total of 353 physicians were recruited to review MRU over the previ-
ous 24 month period from the records of 1,055 patients, with each clinician selecting 
the last three patients representing three different chronic kidney disease stages. 
Data collected included patient characteristics and MRU such as tests, visits, hospi-
talisations and medications. Results: The proportion of patients who had a kidney 
ultrasound during the 24 months study period varied from 20.0% in Sweden to 68.0% 
in Germany. In all countries, except Germany (66.0%), at least 90% of patients had 
one or more contact with a specialist. Annualised specialist visits varied from 2.7 
(SD 7.9) in Germany to 6.0 (SD 10.7) in Sweden. Germany had the largest proportion 
of patients with hospitalisations related to ADPKD (25.7%) whereas Sweden had 
the lowest (13.3%). Hospital length of stay was longest in Spain (mean, 8.5 days (SD 
6.2)) and shortest in the UK (mean, 4.7 days (SD 3.8)). In terms of medication use, 
32.7% of German patients were prescribed loop diuretics whereas this proportion 
was 9.0% in the UK. The UK had the highest rate of opioid use for renal pain overall 
(8.7%) and among patients on dialysis (27.3%). ConClusions: This is the first study 
to provide comparative evidence on MRU in European patients with ADPKD. Results 
highlight some country-specific differences in treatment patterns, including rates 
of hospitalisation, frequency of specialist visits and medication use.
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objeCtives: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
common type of polycystic kidney disease (PKD) and the fourth leading cause of end-
stage renal disease. Currently, there is no published information on medical resource 
utilisation (MRU) in patients with ADPKD in Europe. This study aimed to better 
understand MRU associated with ADPKD by disease stage in six European countries 
(Germany, France, the United Kingdom, Italy, Spain and Sweden). Methods: This 
study was a retrospective review of medical charts collected via an online physician 
survey. Participating physicians abstracted data for the last three eligible ADPKD 
patients treated in their practice, each within a different Chronic Kidney Disease 
(CKD) stage. Data collected over the past 2 years included socio-demographics, 
clinical characteristics and MRU, such as diagnostic tests, specialist visits, dialysis, 
emergency department visits, inpatient admissions and medications. Results: 
A total of 1,055 ADPKD patients were enrolled. The mean (SD) age of the sample 
was 50.4 (14.4) years, 53.6% were male, with 39.4% employed full time. Only 40% of 
patients had a known PKD genotype, of which 83% had PKD-1 and 17% had PKD-
2. Almost all patients (99.1%) experienced at least 1 ADPKD-related complication, 
most commonly hypertension (75.4%). On average (SD), patients had 4.4 (9.3) annual 
specialist visits. Approximately 19.7% of patients experienced at least 1 hospitalisa-
tion over the 2 year study period with a mean (SD) length of stay of 7.0 (8.5) days. 
Patients in more advanced disease stages reported higher mean (SD) annual spe-
cialist visits and more disease-related hospitalisations, 1.5 (1.1) and 9.2% in CKD 
Stage 1 compared to 10.0 (17.2) and 32.4% in Dialysis, respectively. ConClusions: 
This is the first study to provide evidence on MRU among patients with ADPKD in 
Europe. Results demonstrate that ADPKD patients require substantial MRU, which 
accumulate with disease progression.
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objeCtives: Von Willebrand Disease (VWD) is the most common inherited bleeding 
disorder, caused by a deficiency or abnormality of the Von Willebrand factor (VWF). 
Long-term prophylaxis (LTP) with Factor VIII-containing VWF product (FVIII/VWF) is 
used for patients with severe VWD. However, FVIII/VWF is not enough effective in 
some cases. Furthermore repeated infusions of FVIII/VWF may increase the risk of 
thromboembolic events. The objective of the analysis was to assess the economic 
impact of VWF concentrate almost devoid of FVIII as an alternative to FVIII/VWF for 
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Capsaicin 8% patch is cost-effective compared to pregabalin for patients who have 
failed one or more previous systemic treatments for PNP.
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objeCtives: Multiple regimens are used in the treatment of severe haemophilia A 
in the Netherlands. Most patients receive clotting factors intravenously 2-3 times 
weekly to prevent bleedings: intermediate dose prophylaxis. Given the high utili-
zation of prophylaxis treatment, budget restraints might hinder the availability of 
prophylaxis for patients in the nearby future. Other treatment regimens are on-
demand (OD) treatment, administering clotting factors in case of bleedings, and 
prophylaxis treatment with a switch to OD at 18 years. This analysis estimates 
the cost-effectiveness of Dutch prophylaxis treatment for severe haemophilia A 
patients compared to other treatment regimens. Methods: A Markov model is 
developed with the health stages ‘Alive’, ‘Severe joint damage’ and ‘Death’. Bleeding 
rates of individual patients are simulated over lifetime, including a probability of 
inhibitor development. A higher joint bleed rate is accompanied by increased joint 
damage, increasing the chance of joint surgery. Disease progression, within the 
Alive health state, is modeled with the Pettersson Score (PS). The PS indicates the 
radiographic arthropathy. Increased joint damage is associated with physical limita-
tions and decreased QoL. Because the chosen treatment regimen affects both the 
joint bleed rate and inhibitor development, it also affects the HRQoL. The analysis 
was performed from a societal perspective. Results: Prophylaxis treatment was 
associated with the greatest QoL. The cost-effectiveness acceptability curve shows 
a probability of 90% for prophylaxis treatment to be cost-effective at a threshold of 
€ 0, - compared to OD treatment. Compared to prophylaxis with a switch to OD at 
18 years, prophylaxis treatment has a 50% probability of being cost-effective at a 
€ 80.000, - threshold. The model outcome is sensitive for variations in bleeding rate, 
prophylaxis dosage, inhibitor development and utilities. ConClusions: Based on 
our model, treatment of severe haemophilia A patients with lifetime prophylaxis 
is cost-effective compared to OD treatment.
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objeCtives: The objective of the analysis was to evaluate costs and outcomes 
of treating post-herpetic neuralgia (PHN), a chronic disease with severe burden 
for patients, in the Netherlands with lidocaine 5% medicated plaster compared to 
pregabalin and amitriptyline. Methods: A Markov model was used to extrapolate 
outcomes beyond the time horizon of the available trial data and to allow for the 
fact that patients may discontinue treatment at any point during treatment. Costs 
and effects, expressed in terms of the quality-adjusted life-year (QALY) gained, 
were calculated for each treatment strategy over a period of 6 months. The study 
included direct costs related to PHN. Indirect costs were not included as most 
patients with PHN are older and retired. Transition probabilities were based on 
the comparative and long-term clinical trials. Utilites were identified through a 
literature review. Resource utilization was obtained from a two-step Delphi study 
with pain specialists, cost data were obtained from the official price tariffs/lists. 
Extensive sensitivity and scenario analyses were performed to explore robustness of 
the results. Results: In 6-month time horizon, treatment with the lidocaine plaster 
yielded 0.4283 QALYs. For pregabalin and amitriptyline the total effect was 0.3390 
QALYs. The mean costs per patient treated with lidocaine plaster (1.71 plasters/day) 
were 1,082 € . For pregabalin (488 mg/day) and amitriptyline (25 mg/day) the mean 
costs were 912 € and 346 € , respectively. Therefore, the lidocaine plaster compared 
to pregabalin and amitriptyline had an incremental cost-effectiveness ratio of 1,907 
€ /QALY and 8,246 € /QALY, respectively. Probability of the lidocaine plaster being 
cost-effective versus pregabalin and amitriptyline exceeded 90% when considering 
a threshold of 30,000 € per QALY gained. Extensive scenario and one-way sensitivity 
analyses confirmed robustness of the results. ConClusions: The lidocaine 5% 
plaster is a highly cost-effective treatment for PHN in the Netherlands.
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objeCtives: The main objective was to perform a pharmacoeconomic analysis 
to find out the cost effectiveness of diethylpropion (DEP) with diet and exercise. 
(DEP+DaE), compared against Diet and Exercise (DaE) in the treatment for obesity 
from the institutional point of view in Mexico. Methods: Effectiveness data from 
a mexican clinical trial (Morin, 2007) was used to populate a decision tree model 
to estimate the cost-effectiveness of DEP+DaE and its comparator DaE. The target 
population were men and women over 18 years with BMI > 30 kg/m2. Principal 
outcome was the reduction of the Body Mass Index (BMI); benefit was expressed as 
the percentage of patients who reduced more than 10% of their initial weight. Only 
direct medical costs were used, such as medications and adverse events; these were 
obtained from the portal shop by IMSS and also from their unitary costs. To prove the 
Years Gained - LYG) and cost-utility analysis (Quality- Adjusted Life years – QALYs) 
were performed for a time horizon of 10 years according to a Markov economic 
model with four health states - “progression free survival (PFS) in first and second 
lines”, “progression” and “death” - and monthly cycles. Health states transition 
probabilities were obtained from two randomized controlled clinical trials: PRIMA 
(Salles G. et al 2010) and EORTC 20981 (van Oers M. et al 2010). Health state utili-
ties were obtained from literature (Pettengell R. et al 2008). Resource consumption 
was estimated by a Portuguese expert’s panel. Costs were calculated considering 
the Portuguese Health System perspective through official data (unit costs: € in 
2014). Costs and consequences were discounted at 5% per annum. Deterministic 
and probabilistic (Monte Carlo simulation) sensitivity analyses were performed for 
several assumptions namely time horizon, PFS supportive care and progression 
costs; adverse events costs; health states utilities values and costs and benefits 
annual discount. Results: For a 10 years’ time horizon, the cost per LYG and QALYs 
gained was € 10,630 and € 10,674 respectively. Sensitivity analyses confirmed the 
base case results for time horizons of 20 and 30 years, ranging between € 7,430 and 
€ 7,155 per QALY gained, respectively. Probabilistic sensitivity analysis confirmed 
the robustness of the model with a cost per QALY gained of € 10,657. The incre-
mental cost-effectiveness acceptability curve shows that rituximab maintenance 
therapy would be cost effective from a willingness to pay of € 12,000 per QALY 
gained. ConClusions: According to the present model rituximab maintenance 
treatment of FL patients who respond to first line induction therapy compared with 
observation is a cost-effective strategy in Portugal.
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objeCtives: The NHS newborn bloodspot screening programme currently screens 
all babies in England for five rare conditions. The objective of this study was to 
assess the cost-effectiveness of expanding the screening programme to include five 
new rare conditions all inborn errors of the metabolism; HCU, MSUD, GA1, IVA, and 
LCHADD. Methods: A decision tree model was built to estimate the cost-effective-
ness of the expanded newborn screening programme. Estimates of the prevalence 
of the five conditions and the test characteristics of screening were taken from 
the literature. Survival and morbidity estimates for the screened and unscreened 
populations were estimated from published case series. Quality adjusted life years 
(QALYS) were estimated from the extended EQ-5D+ (C) which includes a cognitive 
dimension in order to capture the impact of neurological impairment and devel-
opmental delay which are known sequelae of the five conditions. Costs related to 
the marginal cost of the expanded screening programme, management costs of the 
conditions, and costs associated with the sequelae of the conditions were estimated 
from the pilot study of the expanded screening, case reports from the pilot, expert 
elicitation, published guidelines and estimates from the literature. Costs and QALYs 
were multiplied by survival and morbidity estimates to give lifetime estimates for 
the screened and unscreened populations. A probabilistic sensitivity analysis (PSA) 
was conducted. Results: The results from the deterministic analysis and PSA sug-
gests that screening for all five conditions is cost-saving with screening associated 
with lower total costs and higher total QALYs compared to no screening. The incre-
mental net benefit for all five conditions, at a threshold of £25,000 per QALY, was 
between £0.46 for IVA and £5.94 for GA1. ConClusions: Screening for MSUD, HCU, 
IVA, GA1 and LCHADD are each estimated to be potentially cost saving and result 
in increased quality of life compared to no screening.
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objeCtives: PNP is a high-burden disease exacerbated by poor tolerability of con-
ventional oral therapies. Capsaicin 8% patch is a well-tolerated cutaneous treat-
ment for PNP in non-diabetic adults either alone or in combination with other 
therapies. We evaluated the cost-effectiveness of capsaicin 8% patch versus pre-
gabalin in patients with PNP from the perspective of NHS Scotland. Methods: A 
decision tree model was developed considering patients with PNP who had neither 
achieved pain relief nor tolerated conventional first-/second-line treatments. After 
8 weeks’ treatment with capsaicin 8% patch or pregabalin, patients remained on 
therapy or discontinued due to intolerable adverse events. Patients continuing on 
therapy were classified as either responders (≥ 30% decrease in pain from baseline) 
or non-responders. Last-line therapy was given to non-responders and those who 
discontinued treatment. The base-case time horizon was 2 years. Effectiveness, 
discontinuations and quality of life utilities were estimated from a recent head-to-
head study (ELEVATE; NCT01713426). Other inputs were obtained from published 
sources or clinical expert opinion. All costs were based on GBP 2013/14. The results 
were presented as incremental cost-effectiveness ratios (ICERs), i. e. cost per quality-
adjusted life-year (QALY) gained. Model assumptions were tested with scenario 
analyses. Parameter uncertainty was tested using one-way and probabilistic sen-
sitivity analyses. Results: Compared with pregabalin, capsaicin 8% patch was 
dominant versus pregabalin (total cost difference, –£11 and total QALY gains, +0.049). 
Using a 1-year time horizon, the ICER increased to £1,242/QALY. The model was most 
sensitive to variations in time to capsaicin 8% patch retreatment (worse case ICER, 
£7,951/QALY). Capsaicin 8% patch was dominant in six/seven scenario analyses. 
At a willingness-to-pay threshold of £20,000/QALY gained, the probability of cost-
effectiveness for capsaicin 8% patch versus pregabalin was 97%. ConClusions: 
